Ping Qiu,Gang Chen,Yuhong Dai,Hong Qiu. Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line. Oncol Transl Med, 2018, 4: 48-53.
Establishment and characterization of an oxaliplatin-resistant hepatic cancer cell line
Received:April 06, 2018  Revised:May 17, 2018
View Full Text  View/Add Comment  Download reader
KeyWord:hepatocellular carcinoma (HCC); multidrug resistance (MDR); excision repair-cross complementing 1 (ERCC1); oxaliplatin
Author NameAffiliationE-mail
Ping Qiu Oncology Department,Jingzhou Central Hospital tjqiuhong@163.com 
Gang Chen Integration Traditional Chinese Medicine and Weste,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Yuhong Dai Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Hong Qiu Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
Hits: 4122
Download times: 5027
Abstract:
      Objective?The aim of the current study was to establish an oxaliplatin-resistant hepatoma cell line (HepG2/OXA) and investigate the potential mechanisms of its drug resistance. Methods?The hepatoma cell subline, HepG2/OXA, resistant to oxaliplatin (OXA), was established from a parent cell line HepG2, by stepwise exposure to gradually increasing concentrations of OXA over a half-year period. Chemosenstivity of the cytotoxic drugs, OXA, cisplatin (CDDP), adriamycin (ADM), and 5-fuorouracil (5-FU), was determined in HepG2 and HepG2/OXA cells, by the Cell counting kit-8 (CCK8) assay. Cell cycle distribution of HepG2 and HepG2/OXA cells was analyzed by Flow cytometry (FCM). The expression levels of several drug resistance-related proteins, such as P-glycoprotein (P-gp), multidrug resistant protein 1 (MRP1), and excision repair-cross complementing 1 (ERCC1) protein in the two cell lines were tested by the western blot assay. Results?The IC50 of OXA in HepG2/OXA and HepG2 were 136.84 μmol/L and 23.86 μmol/L, respectively. The resistance index (RI) was 5.34. HepG2 was also demonstrated to be cross-resistant to other anti-tumor agents, such as 5-FU, ADM, and CDDP. The percentage of HepG2/OXA cells in the S phase was significantly decreased compared to HepG2 cells (25.58% ± 2.36% vs 14.37% ± 2.54%, P < 0.05), while the percentage of cells in the G0/G1 and G2/M phases showed no statistical difference (respectively 55.29% ± 4.98% vs 56.73% ± 4.56%, P > 0.05, and 24.63% ± 4.81% vs 28.26% ± 3.82%, P > 0.05). The ERCC1 was found to be over expressed in HepG2/OXA cells, while there was no difference in the expressions of P-gp and MRP1 between the multiple drug resistance (MDR) phenotype cell line and its parental cell line. Conclusion?HepG2/OXA showed an MDR ability; the over expression of ERCC1 might be associated with the platinum resistance of the cells, but P-gp and MRP1 are not.
Close